Compare BGS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGS | ZURA |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | 86 | 40 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.5M | 455.4M |
| IPO Year | 2004 | N/A |
| Metric | BGS | ZURA |
|---|---|---|
| Price | $4.08 | $4.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $4.90 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.2M | 643.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | ★ 83.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,828,687,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.67 | $1.00 |
| 52 Week High | $6.38 | $7.25 |
| Indicator | BGS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 33.35 | 35.18 |
| Support Level | $3.98 | $3.96 |
| Resistance Level | $4.66 | $4.12 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.83 | 12.23 |
B&G Foods Inc manufactures, sells, and distributes a range of branded, shelf-stable, and frozen food and household products across the United States, Canada, and Puerto Rico. Its products include frozen and canned vegetables, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, and wine vinegar. The company's main brands include Crisco, Clabber Girl, Bear Creek, Polaner, Underwood, B&G, Grandma's, New York Style, B&M, Baker's Joy, Regina, TrueNorth, Static Guard, SugarTwin and Brer Rabbit. It operates in four reportable segments: i) Specialty, the majoriy revenue generating segment, ii) Meals, iii) Frozen & Vegetables, iv) Spices & Flavor Solutions.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.